• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • Tuberculosis

    Fighting drug-resistant TB was costly. Here's how that's changed

    Nearly universal access to bedaquiline was only secured in 2023 following yearslong effort involving behind-the-scenes negotiations and public challenges by activists and survivors of multidrug-resistant tuberculosis.

    By Andrew Green // 19 September 2024

    It was while she was in a clinic in Cape Town, South Africa, enduring the complicated, agonizing treatment for extremely drug-resistant tuberculosis, that Phumeza Tisile began to question why “there weren’t better medications that had less side effects.”

    In 2010, soon after her initial diagnosis with multidrug-resistant TB, or MDR-TB, Tisile had received a painful injection of the drug Kanamycin. It had caused her to go deaf essentially overnight, but did not stop the disease’s progression. She had not even been told that hearing loss was a potential side effect.

    It was after she was finally cured, more than three years after starting treatment, that Tisile became aware that the drug company, Johnson & Johnson, had actually just developed a safer treatment with fewer risks. The treatment, bedaquiline, had only gained approval from the U.S. Food and Drug Administration, or FDA, in 2012. Had it been available to her it would have prevented her hearing loss and cut her daily pill count from 25 to fewer than 10.

    This article is free to read - just register or sign in

    Access news, newsletters, events and more.

    Join usSign in
    • Global Health
    • Social/Inclusive Development
    • Trade & Policy
    • Private Sector
    • Funding
    • Stop TB Partnership
    • Johnson & Johnson
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Andrew Green

      Andrew Green@_andrew_green

      Andrew Green, a 2025 Alicia Patterson Fellow, works as a contributing reporter for Devex from Berlin.

    Search for articles

    Most Read

    • 1
      Opinion: How climate philanthropy can solve its innovation challenge
    • 2
      Closing the loop: Transforming waste into valuable resources
    • 3
      The legal case threatening to upend philanthropy's DEI efforts
    • 4
      FfD4 special edition: The key takeaways from four days in Sevilla
    • 5
      How is China's foreign aid changing?
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement